Case Report: Trastuzumab deruxtecan therapy for a patient with breast cancer bone marrow metastasis and history of reversible trastuzumab-induced cardiomyopathy

Background The therapeutic landscape of breast cancer is undergoing a transformative shift toward targeted, biomarker-driven, and toxicity-sparing therapies. Despite these breakthroughs across molecular subtypes, managing a visceral crisis remains a formidable clinical challenge that presents severe decision-making dilemmas for oncologists and an overwhelming burden for patients. In particular, treating aggressive breast cancer with bone marrow metastasis (BMM) is complicated by severe cytopenias and a history of trastuzumab-induced cardiotoxicity, creating a delicate balance between anti-neoplastic efficacy and life-threatening toxicity. Case description A 39-year-old female with HER2-positive early breast cancer developed severe left ventricular dysfunction with an ejection fraction (EF) of 35% during adjuvant trastuzumab-pertuzumab regimen, which fully recovered to 55% following treatment discontinuation. Six months later, she presented with an L4–L5 osseous metastasis causing spinal cord compression. First-line metastatic trastuzumab emtansine (T-DM1) was initiated. After 4 cycles, she developed severe, persistent pancytopenia. A diagnostic bone marrow biopsy confirmed active carcinoma infiltration. Due to disease progression and bone marrow failure, she was transitioned to trastuzumab deruxtecan (T-DXd). T-DXd cleared the marrow microenvironment, restored hematopoiesis, and achieved disease control without recurrent cardiotoxicity. Conclusion T-DXd can serve as a potent salvage therapy to clear the bone marrow microenvironment and reverse malignant cytopenias without exacerbating baseline hematological toxicity, even in patients with a history of transient trastuzumab-induced cardiomyopathy.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-16
DOI
https://doi.org/10.3389/fonc.2026.1983654
Primary Topic
HER2/EGFR in Cancer Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Case Report: Trastuzumab deruxtecan therapy for a patient with breast cancer bone marrow metastasis and history of reversible trastuzumab-induced cardiomyopathy

Feyyaz Özdemir, Ümit Çobanoğlu, Atila Yıldırım, Suleyman Karakeci
2 links
Frontiers in Oncology
HER2/EGFR in Cancer Research
article

Case Report: Trastuzumab deruxtecan therapy for a patient with breast cancer bone marrow metastasis and history of reversible trastuzumab-induced cardiomyopathy

Feyyaz Özdemir, Ümit Çobanoğlu, Atila Yıldırım, Suleyman Karakeci
article en

Abstract

Background The therapeutic landscape of breast cancer is undergoing a transformative shift toward targeted, biomarker-driven, and toxicity-sparing therapies. Despite these breakthroughs across molecular subtypes, managing a visceral crisis remains a formidable clinical challenge that presents severe decision-making dilemmas for oncologists and an overwhelming burden for patients. In particular, treating aggressive breast cancer with bone marrow metastasis (BMM) is complicated by severe cytopenias and a history of trastuzumab-induced cardiotoxicity, creating a delicate balance between anti-neoplastic efficacy and life-threatening toxicity. Case description A 39-year-old female with HER2-positive early breast cancer developed severe left ventricular dysfunction with an ejection fraction (EF) of 35% during adjuvant trastuzumab-pertuzumab regimen, which fully recovered to 55% following treatment discontinuation. Six months later, she presented with an L4–L5 osseous metastasis causing spinal cord compression. First-line metastatic trastuzumab emtansine (T-DM1) was initiated. After 4 cycles, she developed severe, persistent pancytopenia. A diagnostic bone marrow biopsy confirmed active carcinoma infiltration. Due to disease progression and bone marrow failure, she was transitioned to trastuzumab deruxtecan (T-DXd). T-DXd cleared the marrow microenvironment, restored hematopoiesis, and achieved disease control without recurrent cardiotoxicity. Conclusion T-DXd can serve as a potent salvage therapy to clear the bone marrow microenvironment and reverse malignant cytopenias without exacerbating baseline hematological toxicity, even in patients with a history of transient trastuzumab-induced cardiomyopathy.

Frontiers in OncologyVol. 16
Karadeniz Technical University (TR)
Good health and well-being
HER2/EGFR in Cancer Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon